Sana Biotechnology Inc - Asset Resilience Ratio
Sana Biotechnology Inc (SANA) has an Asset Resilience Ratio of 23.97% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Sana Biotechnology Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Sana Biotechnology Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see balance sheet size of Sana Biotechnology Inc.
Liquid Assets Composition Over Time
This chart breaks down Sana Biotechnology Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore Sana Biotechnology Inc (SANA) long-term investment share to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $103.42 Million | 23.97% |
| Total Liquid Assets | $103.42 Million | 23.97% |
Asset Resilience Insights
- Good Liquidity Position: Sana Biotechnology Inc maintains a healthy 23.97% of assets in liquid form.
- This level provides good financial flexibility while maintaining productive asset deployment.
- The company has significant short-term investments, indicating active treasury management.
Sana Biotechnology Inc Industry Peers by Asset Resilience Ratio
Compare Sana Biotechnology Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
argenx NV ADR
NASDAQ:ARGX |
Biotechnology | 15.95% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Shanghai RAAS Blood Products Co Ltd Class A
SHE:002252 |
Biotechnology | 2.03% |
|
Halozyme Therapeutics Inc
NASDAQ:HALO |
Biotechnology | 12.71% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH |
Biotechnology | 33.23% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 65.12% |
Annual Asset Resilience Ratio for Sana Biotechnology Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Sana Biotechnology Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 15.95% | $66.51 Million | $416.89 Million | +10.98pp |
| 2024-12-31 | 4.98% | $24.93 Million | $501.02 Million | -7.70pp |
| 2023-12-31 | 12.68% | $71.68 Million | $565.30 Million | -17.37pp |
| 2022-12-31 | 30.05% | $247.20 Million | $822.72 Million | +3.66pp |
| 2021-12-31 | 26.38% | $297.97 Million | $1.13 Billion | -8.32pp |
| 2020-12-31 | 34.71% | $253.46 Million | $730.30 Million | +20.51pp |
| 2019-12-31 | 14.20% | $58.95 Million | $415.19 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $34.33 Million | -- |
About Sana Biotechnology Inc
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines in the United States. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including type 1 diabetes, B cell mediated autoimmune diseases, and oncology. The company's product pipeline includes UP421, a HIP-modified allogeneic primary… Read more